Recombinant zaire ebolavirus KIKWIT-95 envelope glycoprotein modified vesicular stomatitis virus clinical trials
Also written V920 and BPSC-1001.
How each study uses recombinant zaire ebolavirus KIKWIT-95 envelope glycoprotein modified vesicular stomatitis virus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Merck Sharp & Dohme LLC (2) · National Institutes of Health Clinical Center (CC) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Centers for Disease Control and Prevention (1)
Often tested with
Tested in the same studies.
Ebola Vaccines (1)
Studies
Open first, then newest update. How each study uses recombinant zaire ebolavirus KIKWIT-95 envelope glycoprotein modified vesicular stomatitis virus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine)CompletedPhase 2National Institutes of Health Clinical Center (CC)NCT02788227Written as rVSV∆G-ZEBOV-GP Vaccine (V920)
- Partnership for Research on Ebola VACcinationsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02876328Written as rVSVΔG-ZEBOV-GP
- Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT02269423Written as V920
- Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT02280408Written as V920
- STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)CompletedPhase 2/3Centers for Disease Control and PreventionNCT02378753Written as rVSVΔG-ZEBOV